<i>Genes, Cells and Brains</i> by Hilary Rose and Steven Rose - Review
By Steven Poole,
The Guardian (UK)
| 12. 19. 2012
We have outsourced the job of interpreting ourselves to the modern life sciences. The decoding of the human genome will tell us who we really are, pledged the gene-merchants. Brain scans will tell us who we really are, swore the neuro-hustlers. And what did we get? We got suckered. It turns out that humans have roughly as many protein-encoding genes as a fruit fly, and that
fMRI scanning is still such an inexact art that a team of satirical neuroscientists have demonstrated significant "brain activity" in a dead salmon.
This fascinating, lucid and angry book by the sociologist Hilary Rose and the neurobiologist Steven Rose (they are married) boasts abundant targets and a lethally impressive hit ratio. They decry the entrepreneurialisation of science – "wealth creation is now unabashedly formalised as the chief objective of science and technology policy" – not least because it actually impedes science. ("PhD students can work for months on a project only to find that they cannot continue as they have run into a patent.") They lambast the "armchair" theorising of evolutionary psychology, with its...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...